Biogen (BIIB) Tops Q4 EPS by 8c; FY17 Rev Guidance Falls Below the Street

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Biogen (BIIB) Tops Q4 EPS by 8c; FY17 Rev Guidance Falls Below the Street

Biogen Reports 2016 Revenues of $11.4 Billion

January 26, 2017 6:30 AM EST

2016 GAAP diluted EPS rise 10%; Non-GAAP diluted EPS rise 19%

Board of Directors Appoints Michel Vounatsos as Chief Executive Officer

SPINRAZATM Approved and Launched in the US for Spinal Muscular Atrophy

Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2016 financial results, including:

Full year total revenues of $11.4 billion, a 6% increase versus the prior year. On a constant currency basis1, total... More